Precision phagotherapy to treat bacterial infections
The search for antibiotics seems to have reached a peak for several decades, and it puts bacteriophages back at the forefront of the solutions to this problem.
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. The Company has thus developed technologies, in compliance with current pharmaceutical standards, to select and produce active phages against resistant and multi-resistant bacteria.
Pherecydes has selected as priority targets three families of bacteria listed by the WHO as being among the most dangerous:Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. These three bacterial infections alone account for over 2/3 of hospital acquiredhospital acquired infections in industrialized countries.
The company has already obtained promising results in humans with its phages in the context of compassionate treatments in France, carried out in a medical setting approved by the French National Agency for the Safety of Medicines (ANSM), in particular for bone and joint infections.
As of the end of 2020, Pherecydes has started the production of phages according to industrial GMP (Good Manufacturing Practices) quality standards and plans to start making anti-Pseudomonas aeruginosa and anti-Staphylococcus aureus phages available in France by the second half of 2021 on the basis of Early Access Programs .